Compare CGNX & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGNX | GKOS |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.9B |
| IPO Year | 1994 | 2015 |
| Metric | CGNX | GKOS |
|---|---|---|
| Price | $53.00 | $115.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $55.08 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 2.8M | 718.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | ★ 9.68 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $9.92 | $23.29 |
| Revenue Next Year | $8.78 | $27.74 |
| P/E Ratio | $78.82 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $22.67 | $73.16 |
| 52 Week High | $59.88 | $130.23 |
| Indicator | CGNX | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 48.33 |
| Support Level | $41.11 | $104.72 |
| Resistance Level | $59.11 | $130.23 |
| Average True Range (ATR) | 2.15 | 4.90 |
| MACD | -0.57 | 0.08 |
| Stochastic Oscillator | 19.33 | 61.75 |
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.